Innovator Spotlight

Celebrating the rich technologies UC San Diego brings to market.

Alessandra Franco, UC San Diego School of Medicine

Highlighted Technology: Regulatory T Cells

1)     Please explain your technology.

Regulatory T cells (Treg) play an important role in maintaining the immune homeostasis preventing autoimmune responses and regulating inflammation.

The heavy constant region of immunoglobulins (Fc) activate Treg that recognize short Fc peptides.

Dr. Franco has identified a set of  immune modulatory peptides that stimulate Treg with great potency.

The novelty resides in exploiting the adaptive immune regulation in a specific manner avoiding immune suppressive therapies, as steroids, that affects many efferent arms of the immune response.


2)    For which indications do you see this technology working?

Any disease that requires immune regulation as Rheumatoid Arthritis or other systemic autoimmune diseases, acute and chronic vasculitis, pediatric inflammatory conditions as Kawasaki disease and other diseases successfully treated with intravenous immunoglobulins (IVIG)


3)     What is the next step to get this treatment into patients?

The model has been developed in Rheumatoid Arthritis and Kawasaki disease. A pre-Investigation New Drug package will be submitted soon.


For licensing or commercialization questions, please contact Devora Rossi, Ph.D. (, Senior Innovation & Commercialization Manager.  

. . . . . .
Rossi's background is in Immunology and she has several years of experience in Business Development in various biotech companies before coming to UC San Diego.